• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.29% Nasdaq Down0.87%

    More On I.TO



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    IntelliPharmaCeutics International Inc. (I.TO)

    2.39 Up 0.08(3.46%) Oct 13
    ProfileGet Profile for:
    IntelliPharmaCeutics International Inc.
    30 Worcester Road
    Toronto, ON M9W 5X2
    Canada - Map
    Phone: 416-798-3001
    Fax: 416-798-3007
    Website: http://www.intellipharmaceutics.com

    Index Membership:N/A
    Full Time Employees:46

    Business Summary 

    Intellipharmaceutics International Inc., a pharmaceutical company, engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its products under abbreviated new drug application stage include Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorders; Effexor XR, a venlafaxine hydrochloride extended-release capsule for depression; Protonix, a tablet for gastroesophageal reflux diseases; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, as well as bipolar and depressive disorders; Lamictal XR, a tablet for anti-convulsant for epilepsy; Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy; and Pristiq, a tablet for depression. The company is also developing Oleptro, a trazodone hydrochloride extended release tablet for treating depression; Coreg CR, a capsule, which is in late-stage development for heart failure and hypertension; OxyContin, a controlled release capsule that is in phase I clinical trial for pain; and Lyrica, a capsule, which is in phase I clinical trial for neuropathic pain. Its non-generic products under development include Rexista, an oral formulation for pain relief; and Regabati XR, a pregabalin extended release capsule that has completed an initial phase I clinical trial for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, and fibromyalgia. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. Intellipharmaceutics International Inc. is headquartered in Toronto, Canada.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on IntelliPharmaCeutics International Inc.

    Key Executives 
    Dr. Isa Odidi Ph.D., MBA, 57
    Co-Founder, Chairman, Chief Exec. Officer and Chairman of the Scientific Advisory Board
    Dr. Amina Odidi Ph.D., 55
    Pres, Chief Operating Officer and Director
    Mr. Domenic Della Penna ,
    Chief Financial Officer
    Mr. John Newell Allport B.A.Sc., M.A., LL.B., 69
    VP of Legal Affairs & Licensing, Sec., Director and Member of Corp. Governance Committee
    Mr. Glenn Neumann ,
    Director of Investor Relations
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.